# Whitehawk Therapeutics, Inc.: financial statements, quarterly

WHWK · Nasdaq · CIK 1422142 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/whwk.md) · [Financials](/companies/whwk/financials.md) · [Filings](/companies/whwk/filings.md) · [Insiders](/companies/whwk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/whwk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.0](/filings/0001628280-24-045698.md) | [6.3 d](/filings/0001628280-25-015269.md) | [5.4](/filings/0001628280-25-023932.md) | [6.2](/filings/0000950170-25-105081.md) | [7.2](/filings/0001193125-25-268895.md) | [7.2 d](/filings/0001193125-26-104158.md) | [7.1](/filings/0001193125-26-212075.md) | [0.0](/filings/0001193125-26-337933.md) | [0.0](/filings/0001193125-25-268895.md) | [0.0 d](/filings/0001193125-26-104158.md) | [0.0](/filings/0001193125-26-212075.md) | [0.0](/filings/0001193125-26-337933.md) |
| Cost of revenue | $m | [0.7](/filings/0001628280-24-045698.md) | [0.9 d](/filings/0001628280-25-015269.md) | [0.7](/filings/0001628280-25-023932.md) | [0.8](/filings/0000950170-25-105081.md) | [0.8](/filings/0001193125-25-268895.md) | [0.8 d](/filings/0001193125-26-104158.md) | [0.8](/filings/0001193125-26-212075.md) | [0.0](/filings/0001193125-26-337933.md) | [0.0](/filings/0001193125-25-268895.md) | [0.0 d](/filings/0001193125-26-104158.md) | [0.0](/filings/0001193125-26-212075.md) | [0.0](/filings/0001193125-26-337933.md) |
| Research and development | $m | [11.9](/filings/0001628280-24-045698.md) | [12.8 d](/filings/0001628280-25-015269.md) | [13.6](/filings/0001628280-25-023932.md) | [13.1](/filings/0000950170-25-105081.md) | [10.0](/filings/0001193125-25-268895.md) | [14.3 d](/filings/0001193125-26-104158.md) | [8.8](/filings/0001193125-26-212075.md) | [48.8](/filings/0001193125-26-337933.md) | [14.3](/filings/0001193125-25-268895.md) | [19.0 d](/filings/0001193125-26-104158.md) | [17.2](/filings/0001193125-26-212075.md) | [12.9](/filings/0001193125-26-337933.md) |
| Selling, general and administrative | $m | [11.2](/filings/0001628280-24-045698.md) | [10.3 d](/filings/0001628280-25-015269.md) | [10.6](/filings/0001628280-25-023932.md) | [7.9](/filings/0000950170-25-105081.md) | [7.2](/filings/0001193125-25-268895.md) | [11.1 d](/filings/0001193125-26-104158.md) | [12.8](/filings/0001193125-26-212075.md) | [5.9](/filings/0001193125-26-337933.md) | [5.2](/filings/0001193125-25-268895.md) | [5.9 d](/filings/0001193125-26-104158.md) | [6.3](/filings/0001193125-26-212075.md) | [5.2](/filings/0001193125-26-337933.md) |
| Operating income | $m | [(17.8)](/filings/0001628280-24-045698.md) | [(17.7) d](/filings/0001628280-25-015269.md) | [(19.5)](/filings/0001628280-25-023932.md) | [(15.6)](/filings/0000950170-25-105081.md) | [(13.4)](/filings/0001193125-25-268895.md) | [(18.9) d](/filings/0001193125-26-104158.md) | [(15.2)](/filings/0001193125-26-212075.md) | [(54.7)](/filings/0001193125-26-337933.md) | [(19.5)](/filings/0001193125-25-268895.md) | [(24.9) d](/filings/0001193125-26-104158.md) | [(23.5)](/filings/0001193125-26-212075.md) | [(18.1)](/filings/0001193125-26-337933.md) |
| Interest expense | $m | [0.1](/filings/0001628280-23-037905.md) | [0.1 d](/filings/0001628280-24-010901.md) | [0.1](/filings/0001628280-24-021657.md) | [0.1](/filings/0000950170-25-105081.md) | [0.0](/filings/0001193125-25-268895.md) | [0.0 d](/filings/0001193125-26-104158.md) | [0.0](/filings/0001628280-25-023932.md) | [0.0](/filings/0000950170-25-105081.md) | [0.0](/filings/0001193125-25-268895.md) | [0.0 d](/filings/0001193125-26-104158.md) | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001628280-24-045698.md) | [0.0 d](/filings/0001628280-25-015269.md) | [0.0](/filings/0001628280-25-023932.md) | [0.0](/filings/0001628280-24-035636.md) | [0.0](/filings/0001193125-25-268895.md) | [0.0 d](/filings/0001193125-26-104158.md) | [0.0](/filings/0001193125-26-212075.md) | [0.0](/filings/0001193125-26-337933.md) | [0.0](/filings/0001193125-25-268895.md) | [0.0 d](/filings/0001193125-26-104158.md) | [0.0](/filings/0001193125-26-212075.md) | [0.0](/filings/0001193125-26-337933.md) |
| Net income | $m | [(16.3)](/filings/0001628280-24-045698.md) | [(16.3) d](/filings/0001628280-25-015269.md) | [(18.3)](/filings/0001193125-25-268895.md) | [(14.6)](/filings/0001193125-25-268895.md) | [(12.5)](/filings/0001193125-25-268895.md) | [(18.3) d](/filings/0001193125-26-104158.md) | [73.0](/filings/0001193125-26-337933.md) | [(52.6)](/filings/0001193125-26-337933.md) | [(17.7)](/filings/0001193125-25-268895.md) | [(23.3) d](/filings/0001193125-26-104158.md) | [(22.2)](/filings/0001193125-26-337933.md) | [(16.6)](/filings/0001193125-26-337933.md) |
| Diluted EPS | $ per share | [(0.60)](/filings/0001628280-24-045698.md) | not reported | [(0.68)](/filings/0001628280-25-023932.md) | [(0.54)](/filings/0000950170-25-105081.md) | [(0.46)](/filings/0001193125-25-268895.md) | not reported | [1.83](/filings/0001193125-26-212075.md) | [(0.76)](/filings/0001193125-26-337933.md) | [(0.26)](/filings/0001193125-25-268895.md) | not reported | [(0.32)](/filings/0001193125-26-212075.md) | [(0.20)](/filings/0001193125-26-337933.md) |
| Basic EPS | $ per share | [(0.60)](/filings/0001628280-24-045698.md) | not reported | [(0.68)](/filings/0001628280-25-023932.md) | [(0.54)](/filings/0000950170-25-105081.md) | [(0.46)](/filings/0001193125-25-268895.md) | not reported | [1.84](/filings/0001193125-26-212075.md) | [(0.76)](/filings/0001193125-26-337933.md) | [(0.26)](/filings/0001193125-25-268895.md) | not reported | [(0.32)](/filings/0001193125-26-212075.md) | [(0.20)](/filings/0001193125-26-337933.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [68.8](/filings/0001628280-23-037905.md) | [62.9](/filings/0001628280-25-015269.md) | [53.8](/filings/0001628280-24-021657.md) | [41.1](/filings/0001628280-24-035636.md) | [30.5](/filings/0001628280-24-045698.md) | [28.7](/filings/0001193125-26-104158.md) | [228](/filings/0001628280-25-023932.md) | [145](/filings/0000950170-25-105081.md) | [37.9](/filings/0001193125-25-268895.md) | [37.6](/filings/0001193125-26-337933.md) | [34.8](/filings/0001193125-26-212075.md) | [85.2](/filings/0001193125-26-337933.md) |
| Current assets | $m | [133](/filings/0001628280-23-037905.md) | [125](/filings/0001628280-25-015269.md) | [103](/filings/0001628280-24-021657.md) | [93.0](/filings/0001628280-24-035636.md) | [77.3](/filings/0001628280-24-045698.md) | [61.3](/filings/0001193125-26-104158.md) | [233](/filings/0001628280-25-023932.md) | [179](/filings/0000950170-25-105081.md) | [165](/filings/0001193125-25-268895.md) | [149](/filings/0001193125-26-337933.md) | [126](/filings/0001193125-26-212075.md) | [192](/filings/0001193125-26-337933.md) |
| Total assets | $m | [140](/filings/0001628280-23-037905.md) | [132](/filings/0001628280-25-015269.md) | [111](/filings/0001628280-24-021657.md) | [102](/filings/0001628280-24-035636.md) | [85.7](/filings/0001628280-24-045698.md) | [70.3](/filings/0001193125-26-104158.md) | [234](/filings/0001628280-25-023932.md) | [181](/filings/0000950170-25-105081.md) | [167](/filings/0001193125-25-268895.md) | [151](/filings/0001193125-26-337933.md) | [127](/filings/0001193125-26-212075.md) | [194](/filings/0001193125-26-337933.md) |
| Current liabilities | $m | [20.5](/filings/0001628280-23-037905.md) | [26.4](/filings/0001628280-25-015269.md) | [19.9](/filings/0001628280-24-021657.md) | [22.1](/filings/0001628280-24-035636.md) | [15.8](/filings/0001628280-24-045698.md) | [17.1](/filings/0001193125-26-104158.md) | [12.3](/filings/0001628280-25-023932.md) | [8.8](/filings/0000950170-25-105081.md) | [9.8](/filings/0001193125-25-268895.md) | [14.5](/filings/0001193125-26-337933.md) | [11.1](/filings/0001193125-26-212075.md) | [11.1](/filings/0001193125-26-337933.md) |
| Total liabilities | $m | [21.5](/filings/0001628280-23-037905.md) | [27.2](/filings/0001628280-25-015269.md) | [20.6](/filings/0001628280-24-021657.md) | [22.8](/filings/0001628280-24-035636.md) | [16.8](/filings/0001628280-24-045698.md) | [17.8](/filings/0001193125-26-104158.md) | [12.3](/filings/0001628280-25-023932.md) | [8.8](/filings/0000950170-25-105081.md) | [9.8](/filings/0001193125-25-268895.md) | [14.5](/filings/0001193125-26-337933.md) | [11.1](/filings/0001193125-26-212075.md) | [11.1](/filings/0001193125-26-337933.md) |
| Shareholders' equity | $m | [118](/filings/0001628280-24-045698.md) | [105](/filings/0001193125-26-104158.md) | [90.5](/filings/0001193125-25-268895.md) | [78.8](/filings/0001193125-25-268895.md) | [68.9](/filings/0001193125-25-268895.md) | [52.5](/filings/0001193125-26-337933.md) | [222](/filings/0001193125-26-337933.md) | [172](/filings/0001193125-26-337933.md) | [157](/filings/0001193125-25-268895.md) | [136](/filings/0001193125-26-337933.md) | [116](/filings/0001193125-26-337933.md) | [183](/filings/0001193125-26-337933.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.0) d](/filings/0001628280-24-045698.md) | [(9.6) d](/filings/0001628280-25-015269.md) | [(19.7)](/filings/0001628280-25-023932.md) | [(9.2) d](/filings/0000950170-25-105081.md) | [(15.7) d](/filings/0001193125-25-268895.md) | [(15.1) d](/filings/0001193125-26-104158.md) | [(11.9)](/filings/0001193125-26-212075.md) | [(53.0) d](/filings/0001193125-26-337933.md) | [(15.4) d](/filings/0001193125-25-268895.md) | [(17.2) d](/filings/0001193125-26-104158.md) | [(22.2)](/filings/0001193125-26-212075.md) | [(14.5) d](/filings/0001193125-26-337933.md) |
| Capital expenditure | $m | [1.1 d](/filings/0001628280-24-045698.md) | [0.8 d](/filings/0001628280-25-015269.md) | [0.7](/filings/0001628280-25-023932.md) | [0.5 d](/filings/0000950170-25-105081.md) | [0.2 d](/filings/0001193125-25-268895.md) | [0.2 d](/filings/0001193125-26-104158.md) | [0.6](/filings/0001193125-26-212075.md) | [0.0 d](/filings/0001193125-26-337933.md) | [0.0 d](/filings/0001193125-25-268895.md) | [0.0 d](/filings/0001193125-26-104158.md) | [0.0](/filings/0001193125-26-212075.md) | [0.0 d](/filings/0001193125-26-337933.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [21.3](/filings/0001628280-23-037905.md) | [26.9](/filings/0001628280-24-021657.md) | [26.9](/filings/0001628280-24-035636.md) | [26.9](/filings/0001628280-24-045698.md) | [27.0](/filings/0001628280-25-023932.md) | [27.0](/filings/0000950170-25-105081.md) | [27.0](/filings/0001193125-25-268895.md) | [39.9](/filings/0001193125-26-212075.md) | [69.1](/filings/0001193125-26-337933.md) | [69.2](/filings/0001193125-25-268895.md) | [69.2](/filings/0001193125-26-212075.md) | [82.9](/filings/0001193125-26-337933.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 57,009,010 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-337933.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.